CRP may predict survival after immunotherapy for lung cancerSeptember 20, 2017Immuno-oncologyLung CancerImmunotherapy
Tocilizumab looks promising for corticosteroid refractory anti-PD-1-related adverse eventsSeptember 20, 2017Immuno-oncologyImmunotherapyLung Cancer
Adding T-vec might help surmount PD-1 resistance in melanomaSeptember 14, 2017Immuno-oncologyMelanomaImmunotherapy
Adverse effects of PD-1/PD-L1 inhibitors varied by tumor type in systematic reviewAugust 28, 2017Immuno-oncologyImmunotherapyMelanomaRenal Cell CarcinomaLung Cancer
FDA approves nivolumab for metastatic CRCAugust 2, 2017GastroenterologyImmuno-oncologyImmunotherapyGastrointestinal Cancer
New SU2C translational team aims to apply CAR T-cell therapy to pancreatic cancerAugust 1, 2017Immuno-oncologyGastroenterologyImmunotherapyGastrointestinal Cancer
Pembrolizumab + rituximab boost response rates in relapsed follicular lymphomaJune 26, 2017ImmunotherapyLymphoma & Plasma Cell DisordersFollicular Lymphoma
Studies provide insight into link between cancer immunotherapy and autoimmune diseaseJune 15, 2017Immunotherapy
VIDEO: Immune therapy effective, durable in treatment-naive melanoma brain metastasesJune 12, 2017MelanomaImmuno-oncologyImmunotherapyCNS/Brain Cancer
VIDEO: Combined immunotherapy strategy shows promise in advanced solid tumorsJune 6, 2017Immuno-oncologyImmunotherapy
Immune-agonist combo has activity against several tumor typesJune 5, 2017Immuno-oncologyImmunotherapyBreast CancerMelanomaRenal Cell CarcinomaGynecologic CancerGenitourinary Cancer
FDA approves pembrolizumab for first-line advanced NSCLCMay 12, 2017Lung CancerImmunotherapyImmuno-oncology
Flu shots may spark immune adverse events in PD-1 blockade for NSCLCMay 7, 2017ImmunotherapyLung CancerImmuno-oncology
Modifying CAR-T with IL-15 improved activity in glioma modelsApril 27, 2017CNS/Brain CancerPediatricsImmunotherapy
